BCMA PET/CT to visualize myeloma and related plasma cell disorders

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective, multicenter diagnostic imaging study evaluates the accuracy and clinical value of BCMA-targeted PET/CT for detecting disease in multiple myeloma and related plasma cell neoplasms. Participants receive 68Ga-BCMA PET/CT scans using a standardized protocol, with imaging findings compared to biopsy results when available. The study also explores how scan results relate to other clinical tests, imaging modalities, and disease burden, and tracks changes over time to relate imaging to treatment response. In a subset, soluble BCMA levels are measured to assess associations with imaging findings. Longitudinal follow-up aims to determine how BCMA PET/CT could influence clinical decision-making and disease monitoring.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* patients with suspected or previously diagnosed multiple myeloma (MM) who were scheduled for bone marrow aspiration or tissue biopsy within two weeks, including those undergoing initial diagnostic evaluation or follow-up/re-evaluation for disease monitoring or relapse;
* patients with confirmed symptomatic MM;
* ability to understand and voluntarily sign written informed consent;
* ability to comply with study procedures;
* Eastern Cooperative Oncology Group (ECOG) performance status ≤2.

Exclusion Criteria:

* pregnancy or lactation;
* inability to comprehend study procedures or cooperate with protocol requirements;
* any other condition judged by the investigator to potentially interfere with study participation.

Where it's running

• Beijing An Zhen Hospital of the Capital University of Medical Sciences
  Beijing, Beijing Municipality, China Recruiting
• Beijing Tsinghua Changgung Hospital
  Beijing, Beijing Municipality, China Recruiting
• Peking University First Hospital
  Beijing, Beijing Municipality, China Recruiting
• the Second Hospital of Hebei Medical University
  Shijiazhuang, Hebei, China Recruiting
• First Hospital of Jilin University
  Jilin City, Jilin, China Recruiting

Study contacts

• Principal investigator: Lei Kang, M.D, Ph.D — Peking University First Hospital
• Study coordinator: Lei Kang, M.D, Ph.D
• Email: kanglei@bjmu.edu.cn
• Phone: 86+13811486428

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• 6MW5311 in adults with relapsed or refractory blood cancers

  This study tests increasing doses of 6MW5311 in adults with multiple myeloma, AML, or CMML to see if it is safe and tolerable and to find a suitable dose for later studies.

  Recruiting Phase 1 Mabwell (Shanghai) Bioscience Co., Ltd. · Shanghai, Shanghai Municipality · NCT07914556

• Tailored exercise program to improve quality of life for adults with hematologic cancers

  This pilot trial tests a personalized 16-week exercise program to see if it’s feasible and helpful for adults with acute myeloid leukemia, lymphoma, or multiple myeloma after first-line treatment.

  Recruiting Gruppo Italiano Malattie EMatologiche dell'Adulto · Roma, Rm and 2 other locations · NCT07912684

• Aspirin vs. rivaroxaban for blood clot prevention in newly diagnosed multiple myeloma

  In newly diagnosed multiple myeloma patients on IMiD-based therapy, this study tests whether aspirin or rivaroxaban is better at preventing blood clots.

  Recruiting Phase 4 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07907211

• Exercise phenotyping before chemotherapy in newly diagnosed multiple myeloma

  This observational study tests whether some newly diagnosed multiple myeloma patients with normal resting heart function already show limited exercise capacity, and whether that limitation relates to subtle heart tissue changes and future heart-related outcomes.

  Recruiting Technical University of Munich · Munich, Bavaria · NCT07851493

• SMS text check-ins to track symptoms for people with plasma cell disorders

  This study tests whether daily SMS symptom prompts are feasible and acceptable for adults starting treatment for multiple myeloma or AL amyloidosis.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT07850284

• Cevostamab with Pomalidomide and Dexamethasone after BCMA-directed CAR T therapy in multiple myeloma

  This study tests if Cevostamab combined with pomalidomide and dexamethasone can help people with multiple myeloma who have already had CAR T therapy and several prior treatments.

  Recruiting at 5 sites Phase 2 Hoffmann-La Roche · Nuremberg, Bavaria and 4 other locations · NCT07825064

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.